Repligen Corporation (RGEN): Price and Financial Metrics


Repligen Corporation (RGEN): $323.26

-0.95 (-0.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

RGEN POWR Grades


  • Growth is the dimension where RGEN ranks best; there it ranks ahead of 90.37% of US stocks.
  • RGEN's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • RGEN ranks lowest in Value; there it ranks in the 27th percentile.

RGEN Stock Summary

  • With a price/earnings ratio of 178.36, Repligen Corp P/E ratio is greater than that of about 96.2% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Repligen Corp is higher than 98.21% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 35.05, Repligen Corp has a higher such ratio than 93.25% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Repligen Corp, a group of peers worth examining would be TECH, VSAT, HZNP, OMCL, and KTOS.
  • RGEN's SEC filings can be seen here. And to visit Repligen Corp's official web site, go to www.repligen.com.

RGEN Valuation Summary

  • RGEN's EV/EBIT ratio is 123.6; this is 321.84% higher than that of the median Healthcare stock.
  • Over the past 243 months, RGEN's price/sales ratio has gone down 6.
  • RGEN's price/earnings ratio has moved up 167.9 over the prior 243 months.

Below are key valuation metrics over time for RGEN.

Stock Date P/S P/B P/E EV/EBIT
RGEN 2021-08-31 30.6 9.7 155.7 123.6
RGEN 2021-08-30 30.6 9.7 155.6 123.6
RGEN 2021-08-27 29.8 9.5 151.7 120.4
RGEN 2021-08-26 29.5 9.4 150.0 119.0
RGEN 2021-08-25 29.6 9.4 150.7 119.6
RGEN 2021-08-24 29.2 9.3 148.7 117.9

RGEN Growth Metrics

  • Its year over year price growth rate is now at 56.1%.
  • Its 5 year cash and equivalents growth rate is now at 1009.67%.
  • The 2 year revenue growth rate now stands at 83.76%.
Over the past 33 months, RGEN's revenue has gone up $324,803,000.

The table below shows RGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 508.505 83.273 99.933
2021-03-31 433.007 62.357 79.561
2020-12-31 366.26 62.625 59.926
2020-09-30 327.086 65.428 43.832
2020-06-30 302.471 65.904 30.939
2020-03-31 285.701 66.958 23.173

RGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RGEN has a Quality Grade of C, ranking ahead of 53.73% of graded US stocks.
  • RGEN's asset turnover comes in at 0.278 -- ranking 160th of 677 Pharmaceutical Products stocks.
  • ORMP, PRGO, and TLGT are the stocks whose asset turnover ratios are most correlated with RGEN.

The table below shows RGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.278 0.588 0.369
2021-03-31 0.257 0.574 0.269
2020-12-31 0.235 0.572 0.186
2020-09-30 0.229 0.576 0.144
2020-06-30 0.215 0.569 0.109
2020-03-31 0.218 0.565 0.109

RGEN Price Target

For more insight on analysts targets of RGEN, see our RGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $267.88 Average Broker Recommendation 1.33 (Strong Buy)

RGEN Stock Price Chart Interactive Chart >

Price chart for RGEN

RGEN Price/Volume Stats

Current price $323.26 52-week high $327.32
Prev. close $324.21 52-week low $138.63
Day low $315.53 Volume 341,100
Day high $325.86 Avg. volume 384,809
50-day MA $264.59 Dividend yield N/A
200-day MA $214.96 Market Cap 17.75B

Repligen Corporation (RGEN) Company Bio


Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.


RGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

RGEN Latest Social Stream


Loading social stream, please wait...

View Full RGEN Social Stream

Latest RGEN News From Around the Web

Below are the latest news stories about Repligen Corp that investors may wish to consider to help them evaluate RGEN as an investment opportunity.

bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia

bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ??-thalassemia.

Yahoo | September 22, 2021

3 Unstoppable Healthcare Stocks to Buy With Just $1,000

Jason Hawthorne (Repligen): Repligen might fly under the radar, but it serves an important role in a fast-growing industry. The stock price reinforces that. The company has benefited from the adoption of biologic drugs over traditional small-molecule chemical compounds.

Yahoo | September 22, 2021

Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug

Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.

Yahoo | September 21, 2021

Repligen Inks $150M Deal to Buy Avitide

Repligen Corporation (RGEN), a provider of bioprocessing technologies and solutions for the manufacture of biological drugs, has inked a $150 million deal to acquire Avitide Inc., a leading chromatography developer. Shares rose 1.1% on the news, closing at $299.88 on September 16. (See Repligen stock charts on TipRanks) Avitide boasts diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines. With Avitide on board, Repligen will be able to accelerate its Proteins business and boost its affinity ligand discovery engine. Avitide is expected to generate $10 million in revenue in 2022 and be accretive to Repligen’s adjusted earnings in 2023. Commenting on the deal, Repligen President and CEO Tony J.

Sheryl Sheth on TipRanks | September 17, 2021

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACH...

Benzinga | September 16, 2021

Read More 'RGEN' Stories Here

RGEN Price Returns

1-mo 17.97%
3-mo 68.70%
6-mo 76.15%
1-year 131.00%
3-year 494.45%
5-year 906.73%
YTD 68.69%
2020 107.17%
2019 75.39%
2018 45.37%
2017 17.72%
2016 8.94%

Continue Researching RGEN

Want to see what other sources are saying about Repligen Corp's financials and stock price? Try the links below:

Repligen Corp (RGEN) Stock Price | Nasdaq
Repligen Corp (RGEN) Stock Quote, History and News - Yahoo Finance
Repligen Corp (RGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1675 seconds.